Last updated: February 24, 2026
Case Overview
Actelion Pharmaceuticals US, Inc. filed patent infringement suit against Alembic Pharmaceuticals Limited on February 22, 2023, in the U.S. District Court for the District of Delaware. The case number is 1:23-cv-00383. The dispute concerns patent rights related to a specific formulation of macitentan, a drug used in pulmonary arterial hypertension (PAH) treatment.
Patent Claims at Issue
Actelion alleges that Alembic infringes U.S. Patent No. 10,927,517, titled "Pharmaceutical Composition," issued February 23, 2021. The patent claims cover a specific crystalline form of macitentan with enhanced stability and bioavailability.
Key Patent Details
| Patent Number |
Title |
Issue Date |
Expiration Date |
Claims |
Scope |
| 10,927,517 |
Pharmaceutical Composition |
2021-02-23 |
2041-02-23 |
20 claims |
Crystalline form of macitentan with specific polymorphs |
Actelion asserts that Alembic's proposed generic versions of macitentan infringe these claims by employing the patented crystalline form or its equivalents.
Allegations and Legal Claims
The lawsuit alleges the following:
- Patent Infringement: Alembic's generic macitentan products infringe the '517 patent by employing the patented crystalline form or equivalents.
- Invalidity Claims: Alembic may assert that the patent is invalid due to obviousness or lack of novelty, although such defenses are typically anticipated.
- Preliminary Injunction: Actelion seeks to prevent Alembic from marketing, selling, or distributing the infringing products during the patent’s enforceable period.
Patent Landscape and Industry Context
The patent covers a specific polymorph of macitentan associated with improved stability and bioavailability, key for PAH therapeutic efficacy. Patent protections in this space are critical due to exposure to patent challenges and the importance of exclusivity to recoup R&D investment.
Patents for crystalline forms of active pharmaceutical ingredients (APIs) are common in the pharmaceutical industry to extend exclusivity beyond basic compound patents.
Litigation Timeline and Potential Outcomes
| Date |
Event |
Implication |
| 2023-02-22 |
Complaint filed |
Initiates patent infringement proceedings |
| Likely pre-trial |
Discovery and claim construction |
Clarifies scope of patent claims and assesses infringement risks |
| Expected trial |
Patent validity and infringement issues |
Judge or jury determines infringement and validity |
| Potential outcome |
Injunctions or damages awarded |
Court may order Alembic to cease sales or pay royalties |
The case may proceed to trial, settle, or be resolved via patent office proceedings such as Inter Partes Review (IPR).
Strategic Implications
- For Actelion: Success hinges on proving that Alembic’s product infringes the patent claims and that the patent is valid.
- For Alembic: Defense strategies include challenging patent validity, proving non-infringement, or invalidity through prior art.
Patent disputes like this typically span one to three years before reaching resolution, impacting market entry plans and royalty negotiations.
Industry Impact
This litigation underscores the importance of crystalline polymorph patents in API formulations. It influences generic manufacturers' development strategies and can delay market entry, affecting drug pricing and access.
Key Takeaways
- The case involves patent rights over a crystalline polymorph of macitentan with a focus on stability and bioavailability.
- Actelion claims infringement by Alembic, which is developing a generic version of the drug.
- The outcome could affect market exclusivity for macitentan and influence litigation strategies across the industry.
- Patent validity defenses and claim construction are central to Alembic’s potential defense.
- The litigation process could take several years, with significant financial and strategic implications.
FAQs
Q1: What is the core legal issue in the case?
A1: Whether Alembic’s generic macitentan infringes the '517 patent covering a crystalline form of the drug.
Q2: How long does patent litigation typically last in cases like this?
A2: Between one and three years, depending on complexity and court procedures.
Q3: Can Alembic challenge the patent’s validity?
A3: Yes, through patent invalidity defenses such as prior art or obviousness arguments.
Q4: What are the potential resolutions?
A4: Settlement, court ruling of infringement or invalidity, or patent invalidation through administrative proceedings like IPR.
Q5: How does this case impact market dynamics?
A5: A ruling favoring Actelion could delay generic entry, maintaining higher prices; a ruling favoring Alembic could lead to market competition and price decreases.
Citations
[1] U.S. Patent and Trademark Office. (2021). Patent No. 10,927,517.
[2] Court filings in Actelion Pharmaceuticals US, Inc. v. Alembic Pharmaceuticals Limited, 1:23-cv-00383.
[3] Industry reports on crystalline polymorph patents and market exclusivity strategies.
